Abstract
Neurotoxicity of drugs is a pathologic condition which is on the rise due to both the wider use of specific antiblastic therapies and the improved clinical and neuroradiologic performance that allow early and specific diagnosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radio-chemiotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197
Brandsma D, Stalpers L, Taal et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461
Sanghera P, Perry J, Sahgal A et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37:36-42
Stupp R, Hegi M (2007) Methylguanine methyltransferase testing in glioblastoma: when and how? J Clin Oncol 25:1459-1460
Macdonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Popolizio, T., Pollice, S., Scarabino, T. (2012). Post Chemotherapy Morphologic MR Imaging. In: Scarabino, T. (eds) Imaging Gliomas After Treatment. Springer, Milano. https://doi.org/10.1007/978-88-470-2370-3_9
Download citation
DOI: https://doi.org/10.1007/978-88-470-2370-3_9
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2369-7
Online ISBN: 978-88-470-2370-3
eBook Packages: MedicineMedicine (R0)